109 results
Page 2 of 6
8-K
EX-99.1
k32r vf0g8sf
9 Nov 22
BeiGene Reports Third Quarter 2022 Financial Results
7:06am
8-K
EX-99.1
i383q7qmuals33hq49
4 Aug 22
BeiGene Reports Second Quarter 2022 Financial Results
7:08am
8-K
EX-99.1
qcp d47t4jdnuj
14 Jun 22
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
5:16pm
8-K
EX-99.1
33d4xfj4t95 vdzjmvfl
27 May 22
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
8:33am
8-K
EX-99.1
wowna7
5 May 22
BeiGene Reports First Quarter 2022 Financial Results
7:06am
8-K
EX-10.1
1qumifz
22 Feb 22
BRUKINSA was granted approval by the European Commission for the treatment of Waldenström’s macroglobulinemia in November 2021
4:10pm
8-K
EX-99.1
ziike 439wkkunxnonk
2 Feb 22
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
4:12pm
8-K
EX-99.1
9dz eb10ai
10 Jan 22
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
7:38am
8-K
EX-99.2
tkhp6nce1t5na
6 Dec 21
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
4:16pm
424B5
zxmh5b0
1 Dec 21
Prospectus supplement for primary offering
5:07pm
424B5
ttgoi t68cbwc6
23 Nov 21
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
8x61k
26 Aug 21
Other Events
4:19pm
8-K
EX-99.1
1fz uhrdicpj
5 Aug 21
BeiGene Reports Second Quarter 2021 Financial Results
4:48pm